, Bas H Bueno-De-Mesquita 6, 7, 8, 9 , Eugène HJM Jansen 10 , Konstantinos K Tsilidis 11, 12 , Antonia Trichopoulou 13, 14 , Elisabete Weiderpass large prospective studies, but these observations may be influenced by bias and it is unknown whether they reflect a causal relationship. We observed that genetically determined higher CRP concentrations were associated with higher risk of colorectal cancer, supporting the hypothesis that elevated CRP is directly involved in colorectal carcinogenesis.
higher CRP concentrations translate into higher colorectal cancer risk. We conducted a prospective nested case-control study within EPIC including 727 cases diagnosed between 1992 and 2003 and 727 matched controls selected according to an incidence-density sampling protocol.
Baseline CRP concentrations were measured in plasma samples by a high sensitivity assay.
Tagging single nucleotide polymorphisms (SNPs) in the CRP gene (rs1205, rs1800947, rs1130864, rs2808630, rs3093077) were identified via HapMap. The causal effect of CRP on colorectal cancer risk was examined in a Mendelian Randomization approach utilizing multiple CRP genetic variants as instrumental variables. The SNPs rs1205, rs1800947, rs1130864 and rs3093077 were significantly associated with CRP concentrations and were incorporated in a CRP allele score which was associated with 13% higher CRP concentrations per allele count (95% confidence interval 8%, 19%). Using the CRP-score as instrumental variable, genetically 2-fold higher CRP concentrations were associated with higher risk of colorectal cancer (odds ratio 1.74, 95% confidence interval 1.06, 2.85). Similar observations were made using alternative definitions of instrumental variables. Our findings give support to the hypothesis that elevated circulating CRP may play a direct role in the etiology of colorectal cancer.
INTRODUCTION
High blood concentrations of the inflammatory marker C-reactive protein (CRP) have been associated with moderately elevated risk of colorectal cancer in several prospective studies 1 .
Recent data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study showed a positive association between circulating CRP and risk of colon but not rectal cancer,
and that the association with colon cancer was independent of a variety of metabolic factors including body mass index (BMI), waist circumference, elevated glycated hemoglobin (HbA1c), elevated C-peptide and reduced high density lipoprotein cholesterol (HDL-C) 2 . However, findings from observational studies relating circulating CRP to risk of colorectal cancer are prone to bias by reverse causation due to inflammatory processes that can originate from occult cancer.
Furthermore, CRP concentrations are influenced by a variety of life-style factors such as obesity 3 , physical activity 4 and diet 5 , that could also influence colorectal cancer risk. Thus, even after adjustment for various potentially confounding factors, as was done in the study in EPIC 2 , residual confounding factors may still distort findings. Hence, from standard observational studies it cannot necessarily be assumed that elevated CRP is directly involved in colorectal carcinogenesis. Mendelian Randomization (MR) is an approach to elucidate whether intermediate modifiable traits such as biomarker concentrations are causally related to disease risk. Under the assumption of the random assortment of alleles at gamete formation, genetic variants associated with biomarker levels can be used as relatively unbiased proxies for biomarker concentrations because they are generally unrelated to confounding factors that typically distort findings from conventional epidemiological studies 6 and they cannot be altered by disease occurrence, thereby circumventing reverse causation. The aim of our study was to investigate whether CRP genetic variants associated with lifelong differences in CRP concentrations translate into differences in colorectal cancer risk. We first estimated the association of those genetic variants with colorectal 6 cancer risk and then performed a formal MR approach by instrumental variable analysis to examine the causal association between elevated CRP concentrations and colorectal cancer risk.
METHODS

Study population
This study was conducted using a nested case-control design within the European Prospective
Investigation into Cancer and Nutrition (EPIC), a large prospective cohort with more than 520 000 participants from 10 countries, aged 25-70 years at recruitment between 1992 and 2000 7 . All participants gave written informed consent. At recruitment, anthropometric measurements and blood samples were taken and the participants completed questionnaires on medical history, medication, sociodemographic and lifestyle characteristics [7] [8] [9] . The EPIC study was approved by the ethics review board of the International Agency for Research on Cancer (Lyon, France) and the local review boards of the participating institutions.
Follow-up procedures
Incident cancer cases were identified through record linkage with regional cancer registries at all study centers except those in Germany, France, Greece, and Naples (Italy), where active followup using a combination of methods, including health insurance records, cancer and pathology registries, and direct contact of participants or next-of-kin, was used. For the present study, the closure dates, defined as the latest date of complete follow-up for both cancer incidence and vital status, ranged from December 1999 to June 2003 for study centers using registry data, and from June 2000 to December 2002 for study centers using active follow-up methods.
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Nested case-control study
Colorectal cancer was defined based on the International Statistical Classification of Diseases, Injury and Causes of Death (10th Revision) as a combination of tumors of the colon (C18.0-C18.7), tumors that were overlapping or unspecified (C18. 8-C18.9) , and tumors of the rectum (C19-C20). For location-specific analyses, overlapping and unspecified tumors were grouped among all colon cancers (C18:0-C18:9). A total of 727 incident cases of colorectal cancer (483 colon, 244 rectal) with available blood samples and DNA were included in the present study.
This number differs from the study on CRP levels and risk of colorectal cancer (1096 cases) 2 in EPIC, because DNA samples from Denmark were unavailable due to local technical and organizational issues that delayed sample retrieval. Using risk set sampling, for each case one control was randomly selected among participants free of cancer at the time of diagnosis of the index case, matched on sex, age at blood collection (2-months to 4-year intervals), study center, and fasting status (<3, 3-6, or >6 hours) . Women were additionally matched on menopausal status (premenopausal, perimenopausal, postmenopausal, or surgically menopausal).
Premenopausal women were matched on phase of the menstrual cycle at blood collection (early follicular, late follicular, ovulatory, early luteal, mid-luteal, or late luteal), and postmenopausal women were matched on current use of hormone replacement therapy (yes/no). The latter matching criteria were used because the nested case-control study was designed to be used for several biomarker studies, including studies on hormonal factors in relation to colorectal cancer risk.
Tagging SNP selection and genotyping procedures
A set of tagging single nucleotide polymorphisms (SNPs) was selected to cover variations in the CRP gene common to populations of European descent. The tagging SNPs were selected via 11 and from a genomewide association study 12 . The final list of selected tagging SNPs was: rs1205 (C>T, 3' untranslated region), rs2794520 (C>T, 3' flanking region), rs1800947 (C>G, exon 2), rs1130864
(G>A, 3' untranslated region), rs2808630 (T>C, 3' untranslated region), rs2794521 (T>C, 5' flanking region), rs3093077 (A>C, 3' untranslated region). Some of the selected SNPs have also been identified in more recently published genome-wide association studies on CRP-levels [12] [13] [14] .
All SNPs have been previously associated with circulating CRP concentrations in epidemiological studies 13, [15] [16] [17] . The selected SNPs were genotyped using TaqMan methodology.
Genotype call rates were >99.2% for all assays. Of the genotyped SNPs, rs2794520 was in high agreement (kappa=0.99) and linkage disequilibrium (r 2 ≥0.80) with rs1205 and rs2794521 was in high agreement with rs2808630 (kappa=0.99). We omitted rs2794520 and rs2794521 from analysis. We assumed an additive genetic model for all CRP-SNP genotypes. Due to the very low number of homozygote variant genotypes in rs1800947 (n=8 with GG genotype) and rs2808630
(n=4 with CC genotype), for these two SNPs the homozygote variants were grouped together with heterozygotes for categorical analyses.
Laboratory analyses
Plasma CRP was measured using a high sensitivity assay (Beckman-Coulter, Woerden, the Netherlands) as described previously 2 .
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Circulating levels of C-peptide, HbA1c, insulin-like growth factor 1 (IGF-1), total cholesterol, triglycerides, HDL-C, low density lipoprotein cholesterol (LDL-C), total and high-molecular weight adiponectin, leptin, soluble leptin receptor (sOB-R), and 25-hydroxy vitamin D have been determined within separate research projects in the same nested case-control study as described previously [18] [19] [20] [21] .
Statistical analysis
Hardy-Weinberg Equilibrium was tested in control participants using the Chi-Squared test.
Baseline characteristics between cases and controls and between SNP genotypes (among controls) were compared using paired t-test, Wilcoxon signed rank test, or Mc Nemar's test.
CRP-values were naturally log-transformed.
To verify whether selected SNPs can be utilized as instrumental variables for MR analysis, the association between selected SNPs and CRP concentrations was quantified using linear regression models with robust variance in controls. Geometric mean CRP concentrations and 95% confidence intervals (95% CI) by genotype and the estimated percent difference in CRP levels per minor allele (with genotypes coded 0, 1 or 2 according to the number of minor alleles) are presented. We created an unweighted CRP-score by counting the alleles of the CRP SNPs that were individually associated with higher CRP concentrations. In addition, a weighted allele score was created by summing each genotype multiplied by its estimated coefficient from the linear regression, divided by the sum of weights 22 . The weighted CRP-score was divided in tertiles for categorical analyses.
10
Using the expectation-maximation algorithm, haplotype frequencies were estimated from the SNPs rs1800947, rs1130864, rs1205, rs2808630 and rs3093077 (JMP Genomics/SAS 9.3).
Haplotypes with a frequency lower than 5% were pooled 23 . Haplotype-specific differences in CRP concentrations were estimated among controls using an additive model with the haplotype associated with the highest CRP concentration as reference.
To explore whether individual SNPs, CRP-scores and CRP haplotypes are associated with risk of colorectal, colon or rectal cancer, we used conditional logistic regression models controlling for matching variables to estimate odds ratios (OR) that can be interpreted as incidence rate ratios. 26, 27 , we also conducted a MR analysis using probit models. Interpretation of coefficients from probit models is less intuitive than odds ratios from logistic regression approaches. In brief, coefficients from probit regression models indicate the estimated change in the probability of the outcome for a one unit change of the exposure. We computed probit coefficients using standard (measured CRP, multivariable adjusted for matching factors and covariables) and instrumental variable (adjusted for matching factors) probit regression. All reported p-values are two-sided. Instrumental variable analyses were performed using the STATA, Version 12.1 (StataCorp, College Station, Texas, USA). All other analyses were performed using SAS Enterprise Guide, Version 4.3 (SAS Institute Inc., Cary, North Carolina, USA).
RESULTS
Genotype frequencies of all CRP-SNPs were consistent with Hardy-Weinberg equilibrium (data not shown). Colorectal cancer cases had a higher BMI and waist circumference than controls, were more often physically inactive and had a higher intake of alcohol, total energy and red and processed meat (Table 1) 
Association between genotype and circulating CRP
The SNPs rs1205 and rs1800947 were associated with lower CRP concentrations per minor allele, while the minor alleles of rs1130864 and rs3093077 were associated with higher CRP concentrations ( Table 2 ). rs2808630 was not associated with CRP. The CRP-score was created by counting the alleles associated with higher CRP concentrations, i.e. the C-alleles of rs1205, rs1800947, and rs3093077, and the A-allele of rs1130864. Each allele count of the unweighted CRP-score was associated with 13% higher CRP, explaining 2% of inter-individual variation in CRP concentrations. The weighted CRP-score was associated with 29% higher CRP per score unit and explained 3% of inter-individual variation.
Five CRP haplotypes with a frequency >5% were identified. The haplotype C-G-C-T-C was associated with 128% higher CRP concentrations than haplotype G-G-T-T-A (Supplemental Table 2 ).
Association between genetic variation in the CRP gene and risk of colorectal cancer
The T-allele of rs1205, which was associated with 19% lower CRP, was also associated with lower risk of colorectal cancer (p-trend 0.01) ( Table 3 ). The A-allele of rs11308864, which was associated with 15% higher CRP, was associated with higher risk of colorectal cancer overall (ptrend 0.04) and in women (p-trend 0.04), but not in men. Table 3 ).
Association between circulating CRP and risk of colorectal cancer
In multivariable adjusted conditional logistic regression models, two-fold higher circulating CRP concentration was associated with a moderately higher risk of colorectal cancer (OR 1.06, 95% CI 1.00-1.13) in the full dataset (1096 case-control pairs) ( Figure 1 ). The association was similar in the present dataset of 727 case-control pairs (OR 1.04, 95% CI 0.97, 1.12).
Associations between CRP and risk of colorectal cancer by using instrumental variables
Using the unweighted CRP-score as instrumental variable, genetically 2-fold higher CRP was associated with 74% higher (95% CI 1.06, 2.85) risk of colorectal cancer ( Figure 1 14 Genetically raised CRP through rs1130864 was significantly associated with higher risk of colorectal cancer, while no association was observed with rs1800947 as instrumental variable and -contrary to the expected-a lower risk of colorectal cancer was observed using rs3093077 as instrumental variable. Using the unweighted or weighted CRP-score as instrumental variables, genetically raised CRP was positively associated with colorectal cancer risk in both men and women, as well as with colon and rectal cancer, although confidence intervals were wide for these subgroup analyses (supplemental figure 1) .
Associations between CRP and risk of colorectal cancer by using standard and instrumental variable probit regression
In standard probit analysis multivariable adjusted for matching factors and covariables, a one-unit increase in log-transformed CRP was associated with a statistically significantly higher probability of colorectal cancer (beta 0.07, 95% CI 0.01, 0.13). In the instrumental variable probit analysis, significant associations between genetically raised CRP and risk of colorectal cancer were observed with the unweighted CRP-score (beta 0.40, 95% CI 0.09, 0.72), rs1205 (beta 0.56, 95% CI 0.25, 0.88) and rs1130864 (beta 0.57, 95% CI 0.18, 0.96) as instrumental variables.
DISCUSSION
In this study, we observed that the CRP SNPs rs1205 and rs1130864 were significantly associated with risk of colorectal cancer in the direction expected from their association with CRP concentrations. In a formal MR approach using multiple genetic variants of the CRP gene and a set of alternative instrumental variable definitions, we observed that genetically raised CRP concentrations were associated with higher risk of colorectal cancer, with significant MR estimates for the unweighted CRP-score, rs1205 and rs1130864 as instrumental variables. These 15 findings give support to the hypothesis that elevated CRP is directly involved in colorectal carcinogenesis.
There is strong evidence for inflammatory processes playing a role in the development of colorectal cancer 28 , which is convincingly supported by the observed association between local inflammation of the colorectal mucosa due to inflammatory bowel disease and colorectal cancer risk 29, 30 . Furthermore, there is evidence that reduction of systemic inflammation induced by weight loss also has tissue-specific consequences, i.e. reduced inflammation in the colorectal mucosa 31 . However, as to date no specific mechanism has been suggested to explain how elevated circulating CRP could directly influence colorectal carcinogenesis 32 and experimental studies on the direct effect of CRP on colorectal cancer cells are scarce. Furthermore, studies investigating whether genetic variation in the CRP gene is associated with inflammatory and/or carcinogenic processes beyond CRP concentrations are scarce. There is some suggestion that CRP itself exerts proinflammatory effects 33 , although in a recent study the inflammatory status of random colonic biopsies was largely unrelated to circulating CRP 34 . On the other hand, it has been shown that CRP induces the expression of adhesion cells, which is an important step in tumorigenesis 35 and could serve as an alternative causal process.
Standard epidemiological studies relating blood concentrations of CRP to risk of colorectal cancer have not always been consistent. As to date, 7 out of 15 prospective studies published between 2003 and 2012 observed significant positive associations between circulating CRP and risk of colorectal cancer 36, 37 . In a meta-analysis from 2008, CRP concentrations were positively associated with risk of colorectal cancer, with stronger associations for colon than for rectal cancer and stronger associations in men than in women 1 . In the most recent and so far largest study in women, the Women's Health Initiative Observational Study, a modest positive association between baseline CRP concentrations and colorectal cancer risk was observed 36 .
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We are aware of three MR studies investigating the potentially causal association between CRP concentrations and risk of colorectal cancer 26, 27, 38 . In the first study, common genotype combinations of 4 CRP-SNPs (rs1205, rs1130864, rs3093077, and rs3091244) were associated with up to 72% higher CRP concentrations, but not with higher risk of colorectal cancer (197 cases) 38 . In the second study using a CRP-score from two CRP-associated SNPs (rs2794520 of the CRP gene and rs1169300 of the HNF1A gene) in an instrumental variable probit model, a non-significantly higher probability of colorectal cancer (116 cases, beta per one unit in log- [39] [40] [41] . While in the so far largest study SNPs in the CRP gene including rs1205 were significantly associated with risk of colon cancer (1, 574 cases) 40 , the SNPs rs1205 and rs1130864 (which were significantly associated with colorectal cancer risk in our study) were not individually associated with risk of colorectal cancer in the Rotterdam Study (189 cases) 39 and the CLUE II cohort (208 cases) 41 . In CLUE II, however, two CRP haplotypes were significantly associated with colorectal cancer risk 41 .
Given that our MR study gives support to elevated CRP playing a causal role in the etiology of colorectal cancer, the critical evaluation of the MR assumptions for the instrumental variables approach 42 is particularly important. In our setting, the three assumptions for instrumental variables were: (1) instrumental variable is associated with CRP concentrations, (2) it is independent of factors that may confound the association between CRP and colorectal cancer, and (3) it is associated with colorectal cancer only through CRP (no pleiotropy, i.e. genetic variants having multiple functions). Regarding the first assumption, four CRP SNPs included in our study were significantly associated with CRP concentrations, and all but two (CRP haplotypes and rs3903077) instrumental variables had F-values >12, thereby not falling below the "weak instruments" threshold (F-value <10) that is typically applied in MR studies 24 . Weak instrumental variables may produce biased effect estimates when there is confounding in the exposure-disease relationship 25 , but the size of bias is inversely related to the F-value 43 .
Therefore, the MR estimates based on the CRP-score (F-value >35) can be considered more reliable than the MR estimates based on rs3903077 (F-value 9.1) or the CRP haplotypes (F-value 8.1). In terms of the second MR assumption, as expected given the random assortment of alleles at conception, none of the potentially confounding factors varied substantially across CRP SNP genotypes or the CRP scores, suggesting that the second assumption is fulfilled. Regarding the third MR assumption, various potentially mediating metabolic factors including C-peptide, HbA1c, and adipokines did not vary across genotypes, arguing against pleiotropic effects invalidating the MR approach 42 . Furthermore, the risk of unknown pleiotropy is reduced by using multiple genetic instruments 42 . The risk of pleiotropy would have been even lower, if CRP-associated SNPs from different genes would have been taken into account 27 . Although CRP-associated SNPs in other genes were not available in the present study, our approach of including only genetic variants located in the CRP gene yielded similar results as in the study by Prizment et al 27 , in which CRP-associated SNPs located in or near 20 different genes were utilized. Nevertheless, we found little attenuation of the association between CRP genetic variation and colorectal cancer risk after additional adjustment for measured CRP concentrations, indicating that the third assumption, also referred to as exclusion restriction assumption 44 , may be violated. While the weak attenuation may simply reflect measurement error in the one-time measured CRP concentrations, a violation of the exclusion restriction assumption may result in biased MR estimates and thus we cannot exclude that the instrumental-variable odds ratios overestimated the true association 43, 44 .
Our study has some limitations such as the modest sample size leading to wide confidence intervals. Therefore, replication in a larger study is desirable. Especially the systematic examination of potentially differential associations by site and sex will only be feasible in larger settings. MR analysis using genetic instruments with two-stage least squares regression can be biased when both the variance explained by the instruments and the sample size are small 45 .
Even though our sample size was limited, the CRP-scores had F-values >35 and explained 2-3% of the inter-individual variance in CRP concentrations. However, we cannot exclude that the association between CRP genetic variation and risk of colorectal cancer is due to chance. It is also a limitation of our study is that we were not able to verify whether CRP or CRP genetic variation was associated with other biomarkers of inflammation and/or colonic inflammation.
Furthermore, it should be noted that we cannot exclude that the here employed CRP SNPs are in linkage disequilibrium with other genetic markers that are associated with colorectal cancer risk via a CRP-independent pathway. Population stratification may have confounded our MR estimates, but given the relatively homogenous European study population and the use of multiple genetic variants as instrumental variables this source of bias is rather unlikely 42 . In general, potential bias by geographical differences and/or differential follow-up procedures (e.g.
active follow-up versus registry data) is likely small in this nested case-control study, because both cases and controls originate from the same source population with the same geographical background and center-specific follow-up procedures and were matched by study center (in 19 addition to other matching factors). Nevertheless, the selected control group may not be fully representative to the source population, since per each case one control participant was selected based on matching criteria. However, this mainly results in a loss of precision of risk estimates, and potential bias is likely to be small and expected to be random.
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CONCLUSION
This MR study utilizing multiple genetic variants of the CRP-gene as instrumental variables
gives support to the hypothesis that elevated CRP is directly involved in colorectal carcinogenesis. Given the modest sample size, the results require cautious interpretation, particularly when referring to sex-specific analyses and subtypes of colorectal cancer. Our findings warrant confirmation by larger MR studies and experimental studies investigating a potential mechanism of action for CRP as a direct contributor to colorectal carcinogenesis. MAF=Minor allele frequency in controls, CRP, C-reactive protein a incorporated in CRP-score Models were unadjusted. 
